16
Participants
Start Date
July 28, 2021
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2022
STC314 injection or Placebo(rate=58.3 mg/hr)
To receive continuous infusion of STC314/Placebo injection at rate 58.3mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
STC314 injection or Placebo(rate=87.5 mg/hr)
To receive continuous infusion of STC314/Placebo injection at rate 87.5mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.
NOT_YET_RECRUITING
The Fourth Hospital of Hebei Medical University, Shijiazhuang
NOT_YET_RECRUITING
Wuhan Jinyintan Hospital, Wuhan
RECRUITING
Wuhan Union Hospital, Wuhan
NOT_YET_RECRUITING
Xiangya Hospital Central South University, Changsha
RECRUITING
Zhongda Hospital Southeast University, Nanjing
Lead Sponsor
Grand Pharmaceutical (China) Co., Ltd.
OTHER
Grand Medical Pty Ltd.
INDUSTRY